M

MEI Pharma
D

MEIP

3.13000
USD
0.00
(0.00%)
قبل الجلسة
حجم التداول
29
الربح لكل سهم
0
العائد الربحي
0
P/E
1
حجم السوق
20,854,742
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARWR
    -1.160
    (-4.06%)
    27.410 USD
    B
    BPMC
    -8.610
    (-7.94%)
    99.770 USD
    C
    CRVS
    0.36000
    (13.85%)
    2.96000 USD
    E
    EXEL
    0.740
    (3.15%)
    24.200 USD
    F
    FATE
    -0.46000
    (-8.61%)
    4.88000 USD
    H
    HRTX
    -0.17000
    (-5.72%)
    2.80000 USD
    I
    INFI
    -0.046100
    (-55.54%)
    0.036900 USD
    M
    MRTX
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار
المقالات

العنوان: MEI Pharma

القطاع: Healthcare
الصناعة: Biotechnology
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.